BD Phoenix PMIC-107, Catalog Number 448417, UDI #s (01)30382904484171, (10)7031818(17)180228(30)0025, IVD. PMIC-107 is a Gram positive AST Only panel used to test antibiotic susceptibility. The inducible macrolide-linosamide-steptogramin B (iMLSb) resistance D-test screen for Staphylococcus species is used to identify phenotypic drug resistance to clindamycin and erythromycin. --- Product is packaged 25 panels to 1 box.
Publicado el 6 de diciembre de 2017 · Inicio del retiro: 11 de mayo de 2017
Resumen
FDA registra el retiro Z-0171-2018 de dispositivos médicos de Clase II, publicado el 6 de diciembre de 2017 e iniciado el 11 de mayo de 2017. Empresa responsable: Becton Dickinson & Co.; Estado: Finalizado; Cantidad reportada: US: 7750 units; Lote: Lot 7031818, Exp. Date 2/28/2018. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
BD has recently confirmed quality control failures, related to a manufacturing issue, for the inducible macrolide-linosamide-streptogramin B (iMLSb) test contained on lot 7031818 of Phoenix panels. The iMLSb resistance D-test screen for Staphylococcus species is used to identify phenotypic drug resistance to clindamycin and erythromycin. As the product should not be used when quality control (QC) fails, it is unlikely that there would be any impact on patient results, however, if a customer does not perform QC testing and uses the panel, there is a potential to incorrectly treat a Staphylococcus infection with clindamycin based on the iMLSb test result. This issue can be detected 100% of the time when used per package insert instructions with iMLSb positive strain S. aureus BAA-977.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Becton Dickinson & Co.
- Distribuidor
- CT, VA, PA, TX, FL, NC, WI, NM
- Lote
- Lot 7031818, Exp. Date 2/28/2018
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.21 de octubre de 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.21 de octubre de 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic use6 de mayo de 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic use6 de mayo de 2026
- FDAParty Tray: Yorgo's Foods PARTY TRAY ORIGINAL HOMMUS NET WT. 32 OZ UPC: 7 56248 10097 1 and Yorgo's Foods6 de diciembre de 2017
- FDABRAINLAB EXACTRAC VERO, Model/Catalog Numbers: 46228 EXACTRAC VERO 3.5 46238 EXACTRAC VERO 3.5 46216 EXACTRAC6 de diciembre de 2017
Preguntas sobre este retiro
¿BD Phoenix PMIC-107, Catalog Number 448417, UDI #s (01)30382904484171, (10)7031818(17)180228(30)0025, IVD. PMIC-107 is a Gram positive AST Only panel used to test antibiotic susceptibility. The inducible macrolide-linosamide-steptogramin B (iMLSb) resistance D-test screen for Staphylococcus species is used to identify phenotypic drug resistance to clindamycin and erythromycin. --- Product is packaged 25 panels to 1 box. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0171-2018 el 6 de diciembre de 2017. Peligro reportado: BD has recently confirmed quality control failures, related to a manufacturing issue, for the inducible macrolide-linosamide-streptogramin B (iMLSb) test contained on lot 7031818 of Phoenix panels. The iMLSb resistance D-test screen for Staphylococcus species is used to identify phenotypic drug resistance to clindamycin and erythromycin. As the product should not be used when quality control (QC) fails, it is unlikely that there would be any impact on patient results, however, if a customer does not perform QC testing and uses the panel, there is a potential to incorrectly treat a Staphylococcus infection with clindamycin based on the iMLSb test result. This issue can be detected 100% of the time when used per package insert instructions with iMLSb positive strain S. aureus BAA-977.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter